Saturday, 31 October 2026European Markets

CROSSWOOD Stock Went Up By Over 28% In The Last 21 Sessions

Loading stream...

crosswood (cros.pa), a reputable real estate company of france, has been in the spotlight recently due to its grand performance in the stock market. known for possessing a prominent portfolio that includes assets such as offices, residential properties and shopping outlets, this establishment operates as a subsidiary of the esteemed compagnie financiere de broceliande. the company's stocks have manifested remarkable fluctuations that need to be evaluated and understood in depth.

recent stock performance

in the past 21 sessions, the strikingly volatile nature of crosswood's stock has been evidenced. the unit price took a massive leap of 28.14%, rising from eur8.35 to an impressive eur10.70 after enduring losses for five straight days. this surge starkly contradicts the performance of the cac 40 (french stock market index), which, on the contrary, registered losses totalling 1.35% after a couple of continuous gains and experienced a drop below eur7,220.92.

trading position

crosswood presently trades at eur10.70, which is significantly lower than its 52-week high of eur17.50. this huge gap indicates a considerable opportunity for its expansion. however, comparing the present trading figure with its 52-week low of eur6.655, we can see that it has made substantial recovery.

profitability analysis

from a profitability perspective, trailing data, particularly from the twelve months prior, show an earnings per share (eps) of eur0.57 and a price-earnings ratio of 18.77. this suggests that investors are willing to pay eur18.77 for every euro of annual earnings which could be seen as over-evaluation. nevertheless, this may be a signal of possible rapid expansion in the future.

volatility analysis

recent volatility analysis is key to understanding crosswood's current market status. the average intraday variation registered over the last week stood at 0.93%, while the monthly and quarterly averages were promisingly at 5.08% and 15.58% respectively.

market momentum indications

the stock of crosswood has been deemed to be in an overbought state according to the stochastic oscillator, which generally prompts a price correction in such stocks. on the brighter side, crosswood seems to have experienced a spike in its trading volume, with the latest reported volume hitting 40, which signifies an impressive surge of 66.66% from its average volume of 12.

in conclusion, despite exhibiting signs of instability lately, crosswood's stocks retain remarkable potential for growth and profitability and warrant close attention in the future.

more news about crosswood (cros.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com